sh-Polypeptide-59 for Hair Regrowth

Evidence Review created on 11/09/2026 using AI4L + evidence-mcp / GPT 6

Also known as: PDGF-B, PDGF-BB, Platelet-Derived Growth Factor B, Becaplermin

Motivation

sh-Polypeptide-59 is a manufactured protein ingredient used in some scalp-care and skin-care products. It is associated with a natural growth signal involved in tissue repair, making it a subject of interest for efforts to preserve hair and restore coverage. For adults focused on health and longevity, hair preservation can matter as part of appearance, confidence, and quality of life, without being a measure of longer survival.

Interest in this ingredient draws on several distinct areas: research on the signals that control hair follicles, experience with growth factors used in wound care, and the development of cosmetic formulations containing multiple peptides. These settings involve different products, routes of delivery, and goals. Understanding what each setting actually tests is central to interpreting claims about a serum applied to the scalp.

This review examines the evidence for hair regrowth, the relevance of experimental mechanisms, potential harms, and the practical questions surrounding formulation, dosing, and monitoring. It distinguishes ingredient-specific evidence from findings about related proteins, prescription products, and mixtures.

Benefits - Risks - Protocol - Conclusion

These sources explain the growth-factor rationale and the gap between experimental biology and cosmetic hair products.

Three directly relevant sources are listed. No verified sh-Polypeptide-59-specific item was located from the six priority experts; incomplete searches on some platforms prevent a definitive absence claim.

Grokipedia

No dedicated sh-Polypeptide-59 article was identified; broad search results do not establish that none exists.

Examine

No Examine article on sh-Polypeptide-59 was found.

ConsumerLab

No dedicated ConsumerLab review of sh-Polypeptide-59 was identified; unrelated search matches and restricted full reports prevent confirming complete absence.

Systematic Reviews

No systematic reviews or meta-analyses for sh-Polypeptide-59 were found on PubMed as of November 8, 2026.

Mechanism of Action

The US Food and Drug Administration (FDA) substance record maps sh-Polypeptide-59 to platelet-derived growth factor B and becaplermin; this identifies a biological relationship, not equivalence between finished products (FDA becaplermin substance record). Platelet-derived growth factor (PDGF, a protein signal involved in tissue repair) can exist as paired chains; PDGF-BB contains two B chains.

  • Target: PDGF-BB activates both alpha and beta PDGF receptors (cell-surface switches responding to the growth signal), so it is not follicle-specific (González 2017).
  • Hair-cycle rationale: Injected PDGF-BB induced anagen (the active hair-growing phase) in mice (Tomita 2006). PDGF-BB also supported proliferation of cultured follicle-associated stem cells (González 2017).
  • Translation barrier: These findings do not establish penetration, retained activity, receptor exposure, or regrowth from a cosmetic applied to intact human scalp. A signaling protein’s presence in an ingredient list does not establish a biologically active dose.
  • Pharmacology: Human scalp half-life, tissue distribution, absorption, and clearance have not been established for these formulations. No validated metabolic-enzyme interaction or dose-adjustment model was identified. Protein breakdown is a plausible disposal pathway, not measured scalp pharmacokinetics (how the body handles an applied substance).

The alternative explanation for improved appearance in a blended serum is an effect of its vehicle or other ingredients; that possibility requires a matched-vehicle comparison.

Historical Context & Evolution

PDGF’s clinical development began in tissue repair rather than hair restoration. Becaplermin’s initial US approval was in 1997 (Regranex label). Its current indication concerns deep diabetic lower-extremity ulcers with adequate blood supply, alongside ulcer care (Regranex label). This history establishes experience with a related pharmaceutical preparation, not a hair indication.

The hair-growth rationale acquired experimental support when PDGF isoforms induced and maintained the growing phase in mouse follicles (Tomita 2006). Later work examined the supporting stem-cell population: loss of PDGF receptor signaling reduced the contribution of these stem cells to follicle structures in mice (González 2017). These experiments explain the biological interest without showing that additional topical growth factor reverses human pattern hair loss.

Commercial translation now includes cosmetic raw materials. BIO-FD&C, which sells the ingredient and therefore has a financial interest in adoption, markets sh-Polypeptide-59 as PDGF-B in a liposomal liquid (a formulation using lipid carriers) (BIO-FD&C PDGF-B product specification). Such formulations connect repair biology with scalp-care marketing. The evidence has evolved from tissue repair to follicle mechanisms and commercial delivery claims; a verified clinical bridge to isolated sh-Polypeptide-59 hair regrowth remains absent from the retrieved literature.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no replicated human trial of the isolated topical ingredient was identified.

Medium 🟩 🟩

No benefit reaches Medium: no controlled human hair-regrowth study of the isolated formulation was identified.

Low 🟩

No benefit reaches Low: no usable human case series or clinical comparison isolating sh-Polypeptide-59 hair regrowth was identified.

Speculative 🟨

Hair Regrowth

Mouse injections promoted the growing phase (Tomita 2006). Follicle-cell experiments support the mechanism (González 2017), but topical human regrowth remains untested in the retrieved evidence.

Benefit-Modifying Factors

  • Formulation and route: Concentration, protein integrity, delivery carrier, and scalp penetration could determine activity. No human comparison establishes which formulation reaches follicles effectively.
  • Hair-loss cause: No response data distinguish inherited pattern thinning, immune-mediated loss, temporary shedding, or scarring loss. Mechanistic results cannot establish regeneration of follicles destroyed by scarring.
  • Baseline biomarkers: No blood PDGF concentration, hormone level, or nutrient threshold predicts response to this ingredient.
  • Sex: No ingredient-specific human evidence establishes different benefits in women and men.
  • Age: Older adults and advanced thinning have not been characterized in clinical response studies; age alone cannot supply a response estimate.
  • Genetics: No validated genetic test predicts response or identifies an effective dose.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High for cosmetic scalp use: replicated direct human safety studies were not identified.

Medium 🟥 🟥

No risk reaches Medium for this formulation: controlled evidence concerns different pharmaceutical preparations applied to ulcers.

Low 🟥

Local Rash and Irritation ⚠️ Conflicted

Becaplermin ulcer studies reported rash (Smiell 1998). The label reports equal rash frequency with drug and placebo (Regranex label). It also identifies possible preservative irritation (Regranex label). This is indirect formulation evidence: reactions are possible, but a peptide-specific excess is unproven.

Magnitude: Rash occurred in 2% with becaplermin versus 1% with placebo in the safety overview’s patients with suspected wound infections (Smiell 1998). The current label separately reports 2% versus 2% in clinical trials (Regranex label). These describe ulcer preparations, not scalp-serum incidence.

Cancer Promotion ⚠️ Conflicted

An early higher-exposure cancer-death signal weakened with longer follow-up in becaplermin users (Ziyadeh 2011). Larger cohorts in the current label found no excess mortality (Regranex label). Evidence is indirect and does not establish cancer causation or quantify long-term cosmetic scalp risk.

Magnitude: In the label’s cohort without prior cancer, cancer deaths numbered 197/6,429 exposed versus 206/6,429 unexposed; hazard ratio (comparison of event rates over follow-up) 0.9, 95% confidence interval (range expressing statistical uncertainty) 0.8–1.2 (Regranex label). This excludes neither every small risk nor risks from different scalp exposure.

Speculative 🟨

Unwanted Local Tissue Growth

PDGF signaling stimulates supporting cells (González 2017). Excess connective-tissue growth is a mechanistic concern; controlled human scalp data establishing fibrosis (excess scar-like tissue) from sh-Polypeptide-59 were not identified.

Risk-Modifying Factors

  • Skin condition and delivery: Inflamed, abraded, or deliberately punctured scalp could change exposure and irritation. This is a mechanistic inference; the increase in risk is unquantified.
  • Cancer history: Regranex is contraindicated at an application-site neoplasm (abnormal growth, including cancer) (Regranex label). The label calls for weighing benefits and risks with known malignancy (Regranex label). These pharmaceutical warnings inform caution by analogy; cosmetic risk remains unquantified.
  • Sex and reproductive state: No sex-specific scalp safety estimates exist. Pregnancy and breastfeeding safety are unestablished; absence of data cannot determine fetal or infant risk.
  • Age: No older-adult scalp safety subgroup was identified. Greater willingness to undertake intensive treatment does not resolve uncertainty about cumulative exposure.
  • Biomarkers and genetics: No validated blood threshold or genetic variant predicts toxicity. Normal routine laboratory results would not establish local growth-factor safety.

Key Interactions & Contraindications

No human interaction studies were identified for cosmetic scalp use. Interactions with prescription drugs, nonprescription medicines, or oral supplements—including purported additive hair-growth supplements—remain uncharacterized. Regranex use alongside other topical drugs is also unstudied (Regranex label).

Documented interactions:

  • None identified

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Barrier-disrupting treatments: Microneedling, ablative lasers, or irritating topical products such as tretinoin could increase penetration by disrupting the skin barrier, potentially increasing irritation or unwanted tissue exposure. No validated timing interval or dose correction mitigates this uncertainty.

Populations who should avoid sh-Polypeptide-59:

  • Application-site cancer: Avoidance is inferred from the growth-promoting mechanism and Regranex’s application-site neoplasm contraindication; no direct cosmetic scalp harm study establishes the risk (Regranex label).
  • Known sensitivity to the formulation: Avoidance is inferred from the risk of repeat irritation or allergic response to the same ingredients. No sh-Polypeptide-59-specific allergy threshold or testing protocol is established.

Risk Mitigation Strategies

Uncited practical parameters reflect common topical-product practice, not a validated sh-Polypeptide-59 safety protocol.

  • Application-site reactions: Interruption and assessment of persistent irritation can limit continuing exposure; the related Regranex label describes interruption or discontinuation and possible patch testing for application-site reactions (Regranex label).
  • Local growth concerns: Documentation of pre-existing lesions and assessment of new persistent growths address the uncertainty around local tissue stimulation. No measured stopping threshold has been validated for cosmetic scalp use.
  • Exposure control: Keeping topical cosmetics away from deliberate skin puncture avoids an unmeasured change in tissue exposure. Cosmetic purity specifications do not establish suitability for injection or delivery through damaged skin.
  • Attribution: Recording product changes and avoiding simultaneous introduction of several scalp treatments improves identification of the cause of irritation. It does not establish long-term safety.

Therapeutic Protocol

Uncited practical parameters reflect common topical-product practice; no established therapeutic regimen for isolated sh-Polypeptide-59 hair regrowth was identified.

  • Dose: BIO-FD&C specifies 1–10 parts per million in cosmetics, a commercial formulation range, not a clinically validated hair-regrowth dose (BIO-FD&C PDGF-B product specification). No evidence-based application volume, scalp area, or dose escalation is available.
  • Route: Topical cosmetic use, pharmaceutical wound treatment, and experimental injection are distinct exposures. Neither a wound-gel regimen nor a mouse injection schedule supplies a human scalp protocol.
  • Timing: Morning versus evening, single versus split applications, and minimum contact time have not been compared. There is no established best time of day.
  • Half-life: Human scalp residence time and systemic half-life for a finished cosmetic formulation are unknown; dosing intervals cannot be derived from a measured half-life.
  • Personalization: No validated dose adjustment exists for sex, age, genetics, or baseline biomarkers. Hair-loss diagnosis and scalp disease affect interpretation, but no condition-specific regimen has been established.
  • Practitioner approaches: No independently validated leading-practitioner protocol isolating this ingredient was identified. Commercial multipeptide regimens cannot establish the contribution or optimal dose of sh-Polypeptide-59.

Discontinuation & Cycling

  • Treatment duration: Short-term versus lifelong use has not been resolved by human scalp trials. Continued-use claims for a mixture cannot establish duration for this ingredient alone.
  • Withdrawal: No ingredient-specific withdrawal syndrome or measured post-discontinuation hair-loss trajectory was identified. Lack of reports is not proof that any appearance change persists.
  • Tapering: No evidence-based taper exists. Neither gradual dose reduction nor abrupt discontinuation has been compared for maintaining hair outcomes.
  • Cycling: No study establishes that treatment breaks preserve effectiveness or reduce long-term risk. Cycling schedules remain speculative.

Sourcing and Quality

  • Identity: The FDA’s mapping to becaplermin does not establish matching concentration, paired-chain structure, biological potency, sterility, or delivery in cosmetic products (FDA becaplermin substance record).
  • Raw materials: BIO-FD&C supplies a microbial-fermentation-derived liposomal ingredient; this documents availability, not clinical superiority or an independently endorsed finished brand (BIO-FD&C PDGF-B product specification).
  • Quality documentation: Relevant evidence includes batch identity, actual peptide concentration, biological activity, microbial testing, and stability through expiry. Independent testing would strengthen confidence in composition; it would not demonstrate regrowth.
  • Finished formulations: Disclosed amounts and vehicle composition are more informative than a peptide’s position in an ingredient list. No independently validated brand or compounding preparation can be singled out for this hair-regrowth goal.
  • Storage: Product-specific storage instructions govern stability. Prescription-gel storage requirements cannot automatically be transferred to a different cosmetic vehicle.

Practical Considerations

  • Time to effect: No reliable human time-to-regrowth estimate exists for isolated sh-Polypeptide-59. Mouse hair-cycle timing cannot supply one.
  • Interpretation pitfalls: Improved conditioning, styling, or shaft appearance is not necessarily follicle regrowth. Simultaneous use of other treatments prevents attributing change to this peptide.
  • US regulation: FDA identifies claims to restore hair growth as drug claims, even when a product is marketed as a cosmetic (FDA Cosmetics & U.S. Law). A cosmetic ingredient name does not establish approval for hair loss.
  • Pharmaceutical distinction: Regranex’s labeled use is diabetic ulcer treatment, not hair restoration (Regranex label). Its approval does not validate a different cosmetic formulation.
  • Access and cost: Multi-ingredient cosmetics are commercially accessible, but undisclosed active concentration prevents meaningful cost-per-effective-dose comparisons. A premium price cannot establish additional regrowth.

Interaction with Foundational Habits

  • Sleep: No direct interaction with sleep is established. A topical schedule chosen for convenience has no demonstrated biological timing advantage; disturbed sleep from scalp irritation would be an indirect tolerability issue.
  • Nutrition: No direct dietary interaction or nutrient depletion has been shown. There is no demonstrated food pairing or oral supplement that strengthens this ingredient’s effect; correction of an independently diagnosed deficiency cannot be credited to the peptide.
  • Exercise: No direct effect on training adaptation has been established. Sweat or washing could change contact time, but no human study defines an exercise-to-application interval or establishes its effect on regrowth.
  • Stress management: No direct stress-hormone interaction is established. Stress, shedding, and treatment satisfaction can change together; tracking stress-related changes helps interpret observations without implying that stress management activates the peptide.

Monitoring Protocol & Defining Success

Baseline documentation includes hair-loss pattern, scalp condition, other treatments, and photographs with consistent lighting, hair length, and parting. Clinical assessment distinguishes causes of hair loss. No ingredient-specific blood test has been validated; routine panels cannot confirm scalp safety.

Illustrative tracking, based on common photographic practice rather than a validated protocol, uses baseline and monthly photographs, with review at three and six months. Persistent irritation warrants earlier assessment. These intervals imply no expected response time. Success means reproducible improvement in coverage or density with acceptable tolerability; no minimum meaningful change is established.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hair density in a fixed scalp area No established target; track change from baseline Intended efficacy outcome Same location and measurement method; no validated sh-Polypeptide-59 target.
Scalp redness and persistent lesions No established target; track new changes from baseline Safety check that may change use Clinical assessment of persistent changes; no fasting or blood sampling required.
  • Appearance: Consistent photographs and perceived coverage help distinguish a repeatable change from styling variation.
  • Tolerability: Itching, burning, tenderness, and visible irritation help assess whether the formulation is acceptable.
  • Attribution: An application and co-treatment record documents adherence and competing explanations; an uncontrolled personal observation cannot establish causality.

Emerging Research

  • Clinical trials: No dedicated ongoing ClinicalTrials.gov trial of sh-Polypeptide-59 for hair regrowth was identified as of November 8, 2026. Unrelated PDGF studies of dental healing or facial contour do not establish a hair-growth development program.
  • Mechanism to delivery: Follicle-cell findings motivate tests of active protein delivery into human scalp (González 2017). Demonstrated delivery would strengthen plausibility; absent penetration or lost biological activity would weaken it before clinical effectiveness is considered.
  • Clinical efficacy: A matched-vehicle trial of a chemically characterized formulation could distinguish true regrowth from conditioning and other ingredients. A positive hair-density outcome would strengthen the case; a credible null result would constrain it. No such study was located.
  • Long-term safety: Repeat scalp exposure and use after barrier disruption remain uncharacterized. Pharmaceutical ulcer data offer context, but no scalp-specific estimate; positive or negative surveillance findings could materially alter the current risk uncertainty.

Conclusion

sh-Polypeptide-59 is a cosmetic ingredient linked to a growth-factor protein involved in tissue repair and the biology of hair follicles. The strongest support for hair regrowth comes from animal and cell experiments. Those findings give a coherent reason for interest, but they do not establish that a finished topical product restores hair in people. The expected hair benefit therefore remains speculative.

The safety picture also depends on formulation and exposure. Experience with a related prescription wound gel provides evidence about local reactions and an earlier cancer concern, with later observations offering reassurance in the studied setting. It cannot determine the risks of repeated cosmetic scalp use, particularly when the skin barrier is deliberately disrupted. Supplier specifications establish availability and proposed concentrations, rather than a validated treatment regimen.

For adults prepared to invest time and effort in hair preservation, the central limitation is the absence of a measurable, ingredient-specific clinical benefit against which to weigh uncertain exposure and long-term safety. Commercial suppliers benefit from adoption, while some critical commentary also has competing commercial interests. Product identity, objective tracking, and separation of a peptide’s effects from those of a blend remain essential to interpreting claims. The proposed mechanism could promote hair growth, but dependable regrowth in people has not been demonstrated.

Top - Benefits - Risks - Protocol